文献速递免疫规划传染病防控与疫情报告

二价FHbp脑膜炎球菌B群疫苗可诱导针对非B群菌株的杀菌抗体

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
PubMed 文献 · Vaccine · 2018-09-27

本研究评估MenB-FHbp疫苗接种后诱导的抗体是否对非B群脑膜炎奈瑟菌具有杀菌活性。采用人补体血清杀菌试验检测欧洲、非洲和美国非B群致病菌株,结果显示2或3剂后对C、W、Y、X群杀菌应答率53%–100%,A群20%–28%,均超过保护相关阈值(hSBA≥1:4)。

要点

  • MenB-FHbp接种后对C、W、Y、X群杀菌应答率53%–100%。
  • 对A群杀菌应答率20%–28%,仍高于保护阈值hSBA≥1:4。
  • 四价结合疫苗MCV4对X群无活性,而MenB-FHbp有覆盖。

核心结论

  • MenB-FHbp可能提供不依赖血清群的脑膜炎球菌病保护。

研究设计与样本

  • 采用人补体血清杀菌试验(hSBA)评估MenB-FHbp免疫后血清对非B群致病菌株的杀菌活性。

主要发现

  • 2或3剂MenB-FHbp后,53%至100%个体对C、W、Y、X群菌株产生杀菌应答(hSBA滴度≥1:8)。
  • 20%至28%个体对A群菌株产生杀菌应答,均超过保护相关阈值hSBA≥1:4。
  • 对照MCV4对A、C、W、Y群杀菌应答率90%至97%,对X群无活性。

关键数值与推荐

  • 杀菌应答定义为hSBA滴度≥1:8;保护相关阈值为hSBA滴度≥1:4。

临床怎么用

  • MenB-FHbp或可考虑用于预防非B群脑膜炎球菌病,尤其X群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MenB-FHbp (Trumenba®; bivalent rLP2086) is a meningococcal serogroup B vaccine containing 2 variants of the recombinant lipidated factor H binding protein (FHbp) antigen. The expression of FHbp, an outer membrane protein, is not restricted to serogroup B strains of Neisseria meningitidis (MenB). This study investigated whether antibodies elicited by MenB-FHbp vaccination also protect against non-MenB strains. Immunological responses were assessed in serum bactericidal assays using human complement (hSBAs) with non-MenB disease-causing test strains from Europe, Africa, and the United States. Importantly, FHbp variant distribution varies among meningococcal serogroups; therefore, strains that code for serogroup-specific prevalent variants (ie, representative of the 2 antigenically distinct FHbp subfamilies, designated subfamily A and subfamily B) and with moderate levels of FHbp surface expression were selected for testing by hSBA. After 2 or 3 doses of MenB-FHbp, 53% to 100% of individuals had bactericidal responses (hSBA titers ≥ 1:8) against meningococcal serogroup C, W, Y, and X strains, and 20% to 28% had bactericidal responses against serogroup A strains; in fact, these bactericidal responses elicited by MenB-FHbp antibodies against non-MenB strains, including strains associated with emerging disease, were greater than the serological correlate of protection for meningococcal disease (ie, hSBA titers ≥ 1:4). This is in comparison to a quadrivalent polysaccharide conjugate vaccine, MCV4 (Menactra®, targeting meningococcal serogroups A, C, W, and Y), which elicited bactericidal responses of 90% to 97% against the serogroup A, C, W, and Y strains and had no activity against serogroup X. Together, these results provide clinical evidence that MenB-FHbp may protect against meningococcal disease regardless of serogroup.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018. PMID: 30269916. doi:10.1016/j.vaccine.2018.05.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。